Insulin resistance is one of the most commonly discussed terms in metabolic health, yet it is also one of the most poorly explained. It comes up in conversations about weight gain, PMOS (Polyendocrine Metabolic Ovarian Syndrome, formerly called PCOS), prediabetes, heart disease, and why certain people seem to struggle with their weight in ways that others do not — yet it rarely gets a clear, standalone explanation that connects the mechanism to the symptoms to the practical steps. This article aims to close that gap.
It covers what insulin resistance actually is, how to recognize it, how to test for it, and which interventions have the strongest evidence for improving it. Nothing here replaces a clinical evaluation, but understanding what is happening in your body is a reasonable starting point for an informed conversation with your provider.
What insulin actually does
Insulin is a hormone produced by the beta cells of the pancreas. Its primary job is to serve as a key that unlocks cells and allows glucose (sugar from food) to enter them and be used for energy. When you eat carbohydrates, your blood glucose rises. The pancreas responds by releasing insulin into the bloodstream. Insulin then travels to muscle, liver, and fat cells and binds to insulin receptors on their surface. This binding triggers the cells to take up glucose from the blood, reducing blood sugar back toward baseline.
Beyond glucose regulation, insulin has several other important roles: it signals the liver to stop producing glucose when blood sugar is already adequate, promotes the storage of excess energy as glycogen in the liver and muscle and as fat in adipose tissue, and it has meaningful anabolic effects on muscle, supporting protein synthesis and inhibiting muscle breakdown. Insulin is not simply a blood sugar hormone. It is a master metabolic regulator that touches energy storage, hunger signaling, inflammation, and cardiovascular function.
What insulin resistance actually means
Insulin resistance is the state in which cells no longer respond normally to insulin's signal. The key, so to speak, still fits the lock, but the door is much harder to open. Muscle, liver, and fat cells require increasingly high levels of insulin to take up the same amount of glucose they would have previously taken up with less.
This is why standard fasting glucose can appear normal for years while insulin resistance worsens behind the scenes. The glucose looks fine because the pancreas is overcompensating with elevated insulin. It is the elevated insulin, not elevated glucose, that is the earliest signal of a problem developing.
Over time, if insulin resistance persists, the pancreas may not be able to keep up with the compensatory demand, and blood glucose begins to rise — first into the prediabetes range (fasting glucose 100 to 125 mg/dL, or HbA1c 5.7% to 6.4%) and eventually to frank type 2 diabetes if the underlying resistance is not addressed.
Crucially, elevated insulin levels themselves cause downstream harm independent of blood glucose. Hyperinsulinemia is associated with increased fat storage (particularly in the visceral compartment), higher blood pressure, worsening lipid profiles, increased systemic inflammation, and elevated androgen levels — which is part of why insulin resistance is so central to PMOS. The elevated insulin is not a benign compensatory success story; it carries a real physiological cost.
How common is insulin resistance?
These figures tell part of the story, though the more important clinical point is that insulin resistance is often present for a decade or more before it progresses to prediabetes or type 2 diabetes. The standard annual physical does not screen for it directly. Fasting glucose and even HbA1c can remain normal throughout this period while compensatory hyperinsulinemia quietly drives weight gain, fatigue, hormonal disruption, and cardiovascular risk — making it a largely silent condition in its early stages.
What causes insulin resistance?
Insulin resistance develops through a combination of genetic predisposition and lifestyle and environmental factors. The relative contribution of each varies significantly between individuals, which is why some people develop it with a seemingly modest amount of weight gain while others have substantial obesity and remain relatively insulin sensitive. The following are the most well-established drivers.
Excess visceral adiposity
Fat stored deep in the abdominal cavity, surrounding the organs (visceral fat), is metabolically active in a way that subcutaneous fat is not. Visceral fat releases inflammatory cytokines, free fatty acids, and adipokines that directly interfere with insulin signaling in the liver and muscle. This is why waist circumference is a more sensitive early indicator of metabolic risk than BMI: you can carry significant visceral fat at a normal or moderately elevated BMI.
Ectopic lipid accumulation
When fat accumulates in tissues that are not designed to store it — particularly the liver and skeletal muscle — it produces toxic lipid metabolites (ceramides, diacylglycerols) that disrupt insulin receptor signaling. Non-alcoholic fatty liver disease (now called MASLD) is both a cause and a consequence of insulin resistance, and the relationship is bidirectional.
Chronic low-grade inflammation
Inflammatory signals — particularly TNF-alpha and interleukin-6 — impair insulin receptor signaling at the cellular level. Chronic inflammation, whether from excess visceral fat, sleep deprivation, gut dysbiosis, or other sources, directly worsens insulin sensitivity. This is part of the mechanistic link between poor sleep, stress, and metabolic dysfunction.
Physical inactivity
Skeletal muscle is the body's largest glucose sink. Contracting muscle takes up glucose through insulin-independent pathways, and regular exercise improves insulin receptor sensitivity in muscle cells for 24 to 48 hours following a session. Physical inactivity removes this powerful insulin-sensitizing stimulus and allows insulin resistance to develop even in the absence of significant weight gain.
Sleep deprivation and circadian disruption
A randomized crossover trial published in Obesity (2023) found that four nights of sleep restriction reduced insulin sensitivity by 20% in postmenopausal women, measured by hyperinsulinemic-euglycemic clamp — the gold standard for measuring insulin action. Disrupted circadian rhythms, common in shift workers, compound this effect by desynchronizing the timing of cortisol and insulin secretion.
Genetic and ethnic variation
First-degree relatives of people with type 2 diabetes have significantly elevated baseline insulin resistance. Asian, Hispanic, South Asian, Native American, and Pacific Islander populations develop insulin resistance and type 2 diabetes at lower BMI thresholds than non-Hispanic white populations, which is why standard cutoffs for metabolic screening are actively debated for these groups. Genetics set the baseline; lifestyle determines how quickly the threshold is crossed.
Conditions linked to insulin resistance
Insulin resistance does not exist in isolation. It sits at the center of a cluster of conditions that frequently co-occur and reinforce each other. Recognizing this cluster is part of what makes identifying insulin resistance clinically useful — since treating one part of it often improves the others.
Signs and symptoms to watch for
Insulin resistance often produces no symptoms in its early stages. When it does manifest, the signs are easy to attribute to other causes — which is part of why it goes unrecognized for so long. The following are the most clinically consistent signs, noting that none of them alone confirms a diagnosis.
- Fatigue after meals, particularly carbohydrate-heavy ones. Exaggerated insulin responses cause reactive blood sugar drops after eating, producing post-meal energy crashes and brain fog.
- Difficulty losing weight despite genuine effort. Elevated insulin is powerfully anti-lipolytic. It actively inhibits fat burning. People with significant insulin resistance may lose very little weight on approaches that work well for insulin-sensitive individuals.
- Strong carbohydrate cravings, especially in the afternoon. Blood sugar variability driven by erratic insulin responses creates genuine physiological hunger for quick-energy foods.
- Central weight gain or increasing waist circumference. Visceral fat accumulation is both a cause and consequence of insulin resistance and is often the earliest visible sign.
- Acanthosis nigricans. Dark, velvety skin patches in the neck folds, armpits, or groin, caused by elevated insulin stimulating skin cell growth. This is a reliable physical sign of significant hyperinsulinemia.
- Skin tags, particularly around the neck and armpits. Similarly associated with hyperinsulinemia.
- Elevated blood pressure and triglycerides, low HDL. This lipid pattern is the classic fingerprint of metabolic syndrome and insulin resistance, even when fasting glucose is still normal.
- In women: irregular periods, excess facial hair, or worsening PMOS/PCOS symptoms. Hyperinsulinemia drives ovarian androgen excess and is central to the metabolic-ovarian dysfunction now recognized under the PMOS classification.
How to test for insulin resistance
There is no single perfect test for insulin resistance in clinical practice. The gold standard — the hyperinsulinemic-euglycemic clamp — is a research tool not available in routine care. Clinically practical testing combines several accessible markers to build a picture, though you will likely need to ask for some of them specifically, as they are not included in a standard annual panel.
| Test | What it measures | Key thresholds | Notes |
|---|---|---|---|
| Fasting insulin | How hard the pancreas is working at baseline | <8 mIU/L often cited 10–12+ warrants attention | Not routinely ordered; ask specifically. Reference ranges vary by assay and lab — no universally agreed-upon cutoff exists. HOMA-IR is the more validated clinical screening tool. |
| HOMA-IR | Calculated estimate using fasting insulin × fasting glucose ÷ 405 | <1.5 reference range ≥2.0–2.5 suggests IR ≥3.0 significant | NHANES uses ≥2.5 as the standard cutoff. Asian populations may warrant lower thresholds (1.4–2.5), though ethnic-specific cutoffs remain under active research. |
| Fasting glucose | Blood sugar after an overnight fast | <100 mg/dL 100–125 prediabetes ≥126 diabetes | May remain normal for years despite significant insulin resistance. Least sensitive early marker — important to include but insufficient alone. |
| HbA1c | Average blood glucose over 2–3 months | <5.7% 5.7–6.4% prediabetes ≥6.5% diabetes | Better than fasting glucose alone but still a late-stage marker. Values at the upper end of "normal" (5.5–5.6%) in the context of other risk factors deserve attention. |
| Fasting lipids | Triglycerides, HDL, LDL, total cholesterol | Triglycerides >150 mg/dL with HDL <40 (men) or <50 (women) is a classic insulin resistance pattern | The triglyceride-to-HDL ratio is an inexpensive surrogate for IR. A ratio above 3.0 in white populations (above 2.0 in other groups) correlates with insulin resistance in multiple studies. |
| Waist circumference | Proxy for visceral adiposity | >35 in. women / >40 in. men (standard); lower thresholds apply in Asian populations | Simple, inexpensive, and more predictive of cardiometabolic risk than BMI. Ask your provider to measure it at the navel, or do it yourself at home. |
What actually reverses insulin resistance
Insulin resistance is not fixed. It is a functional state that responds to lifestyle intervention more robustly than almost any other metabolic condition. The following interventions have the strongest and most consistent evidence. Most of them work through multiple mechanisms simultaneously, which is why combining them is more effective than any single approach.
Insulin resistance is not a life sentence. It is a functional state, responsive to consistent lifestyle intervention, and measurable improvement is achievable in weeks to months for most people who address the underlying drivers.
GLP-1 medications and insulin resistance
GLP-1 receptor agonists — including semaglutide and tirzepatide — improve insulin resistance through several mechanisms operating simultaneously. They stimulate insulin secretion in a glucose-dependent manner, suppressing glucagon and reducing hepatic glucose production. By producing significant weight loss, particularly of visceral and liver fat, they address the primary driver of insulin resistance in most people with obesity. Some evidence also suggests direct effects on insulin signaling in muscle and fat cells through GLP-1 receptor activity in those tissues, though these effects are smaller than the weight-loss-mediated improvements.
Tirzepatide, which activates both GLP-1 and GIP receptors, appears to produce greater improvements in insulin sensitivity per unit of weight loss compared to GLP-1 monotherapy — possibly because GIP receptor activity has independent insulin-sensitizing effects on adipose tissue. The SURMOUNT trials documented reductions in fasting insulin, HOMA-IR, HbA1c, and triglycerides alongside weight loss that were not fully explained by the weight reduction alone.
Insulin resistance: clinical evaluation and management framework
Fasting insulin is underutilized in primary care. The standard annual metabolic panel does not include fasting insulin, yet it is one of the most informative early markers of metabolic dysfunction. HOMA-IR, calculated from fasting insulin and fasting glucose, can identify significant insulin resistance years before glucose or HbA1c becomes abnormal. Adding fasting insulin to routine metabolic screening for patients with central adiposity, family history of T2DM, PMOS, hypertriglyceridemia, or low HDL is clinically reasonable and inexpensive.
Triglyceride-to-HDL ratio as a screening surrogate: In populations where fasting insulin is not routinely ordered, a fasting TG:HDL ratio above 3.0 has shown reasonable sensitivity and specificity for insulin resistance in several studies and is available from any standard lipid panel. Some research suggests lower thresholds may be appropriate in non-white populations, though race-specific cutoffs in this area remain under active investigation (Yu et al., Medicine, 2026).
Ethnic-specific thresholds matter: HOMA-IR cutoffs validated in largely European populations (2.0–2.5) may overestimate the threshold at which metabolic risk accumulates in Asian, South Asian, and Hispanic populations. Lower BMI thresholds for metabolic screening are recommended by the ADA, AACE, and WHO for these groups.
Key management considerations:
- Prioritize combined exercise prescription. Both aerobic and resistance training improve insulin sensitivity, and the ADA and ACSM position statements indicate that combined training produces the greatest improvements. For patients with limited time, resistance training and post-meal walking are high-yield starting points. Prescribe exercise specifically rather than offering a general recommendation to be more active.
- GLP-1 medications in the clinical context of insulin resistance: For patients with obesity and significant insulin resistance, GLP-1 and dual GLP-1/GIP agonists address both weight-mediated and potentially direct pathways of insulin sensitization. HOMA-IR improvement with tirzepatide in the SURPASS and SURMOUNT trials was substantial and exceeded what would be predicted by weight loss alone in some analyses.
- Metformin remains underused for prediabetes with insulin resistance: The Diabetes Prevention Program established metformin's benefit for high-risk prediabetic patients, particularly those under 60 with BMI over 35 or a history of gestational diabetes. Its effect on HOMA-IR is modest compared to lifestyle intervention but it is safe, inexpensive, and additive.
- Screen for MASLD in patients with insulin resistance: Liver enzyme elevation (ALT in particular) in the context of metabolic risk factors warrants hepatic evaluation. The FIB-4 index and transient elastography are appropriate first-line tools for stratifying fibrosis risk.
References and sources
- Choo YN, Ravi RN, Subramaniyan V. Insulin resistance induced by obesity: mechanisms, metabolic implications and therapeutic approaches. Mol Biol Rep. 2026;53:247. doi:10.1007/s11033-026-11509-3
- Huang X, Liu G, Guo J, Su Z. The PI3K/AKT pathway in obesity and type 2 diabetes. Int J Biol Sci. 2018;14(11):1483–1496. doi:10.7150/ijbs.27173
- Li M, Chi X, Wang Y, et al. Trends in insulin resistance: insights into mechanisms and therapeutic strategy. Signal Transduct Target Ther. 2022;7(1):216. doi:10.1038/s41392-022-01073-0
- Araújo J, Cai J, Stevens J. Prevalence of optimal metabolic health in American adults: NHANES 2009–2016. Metab Syndr Relat Disord. 2019;17(1):46–52. doi:10.1089/met.2018.0105
- Newsom SA, Everett AC, Hinko A, Horowitz JF. A single session of low-intensity exercise is sufficient to enhance insulin sensitivity into the next day in obese adults. Diabetes Care. 2013;36(9):2516–2522. doi:10.2337/dc12-2606
- Strasser B, Pesta D. Resistance training for diabetes prevention and therapy: experimental findings and molecular mechanisms. Biomed Res Int. 2013;2013:805217. doi:10.1155/2013/805217
- Griffin SJ, Bethel MA, Holman RR, et al. Metformin in non-diabetic hyperglycaemia: the GLINT feasibility RCT. Health Technol Assess. 2018;22(18):1–64. doi:10.3310/hta22180
- Shan Z, Ma H, Xie M, et al. Sleep duration and risk of type 2 diabetes: a meta-analysis of prospective studies. Diabetes Care. 2015;38(3):529–537. doi:10.2337/dc14-2073
- Wu C, Ke Y, Nianogo RA. Trends in hyperinsulinemia and insulin resistance among nondiabetic US adults, NHANES 1999–2018. J Clin Med. 2025;14(9):3215. doi:10.3390/jcm14093215
- Abohashem S, Hassan I, Wasfy JH, Taub PR. Trends and prevalence of the metabolic syndrome among US adults. JAMA. 2026;335(3):274–277. doi:10.1001/jama.2025.21712
- Yu Z, Zhao Z, Sun MZ, Han Y. Triglycerides and HDL cholesterol as strong correlates of insulin resistance: evidence from NHANES 2013 to 2018. Medicine. 2026. doi:10.1097/MD.0000000000041664
- Djiogue S, Nwabo Kamdje AH, Vecchio L, et al. Insulin resistance and cancer: the role of insulin and IGFs. Endocr Relat Cancer. 2013;20(1):R1–R17. doi:10.1530/ERC-12-0324
